# Genome Editing Core

> **NIH NIH P30** · JOSLIN DIABETES CENTER · 2021 · $220,935

## Abstract

CORE 5 - GENOME EDITING CORE: ABSTRACT 
Investigating mechanisms that underlie diabetes and its complications requires relevant experimental models. 
In recent years, induced pluripotent stem (iPS) cells have provided a unique means to study disease-relevant 
molecular pathways in patient-specific cells. The development of genome editing tools such as the CRISPR- 
Cas9 system has made it possible to accurately engineer cells and further refine disease modeling using iPS 
cells. Studies of iPS-derived cells are invaluable to the modeling of human cellular defects. However, cell- 
based experiments do not adequately reflect systemic changes associated with diabetes. Animal models are 
equally important and necessary to complement in vitro experimentation. Genome editing techniques have 
also made it possible to very quickly and efficiently generate new diabetes-relevant mouse models to 
interrogate mechanisms of disease. 
The Genome Editing Core (GEC) will provide a platform for investigators to create novel and unique human 
cellular models and mouse models to study diabetes and its complications. The GEC will use state-of-the-art 
methodology to 1) generate patient-specific iPS cell lines, 2) edit the genome of iPS and iPS-derived cells to 
probe individual genes or gene variants and 3) generate custom mouse models by gene knockdown, knock-in, 
knock-out or replacement. In addition to providing these services, the GEC will offer advice, reagents and tools 
for genome editing of experimental models and offer training for the generation and manipulation of iPS cell 
lines. In collaboration with the newly proposed Clinical Translational Research Core, the GEC will also serve 
as a repository for a large collection of unique iPS cell lines derived from type 1 diabetes, type 2 diabetes and 
MODY patients sourced from Joslin's extensive patient population. In sum, the GEC will constitute an 
invaluable resource for all aspects of diabetes research by facilitating the custom generation of relevant model 
systems.

## Key facts

- **NIH application ID:** 10160880
- **Project number:** 5P30DK036836-35
- **Recipient organization:** JOSLIN DIABETES CENTER
- **Principal Investigator:** Stephan Kissler
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $220,935
- **Award type:** 5
- **Project period:** 1997-02-15 → 2022-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10160880

## Citation

> US National Institutes of Health, RePORTER application 10160880, Genome Editing Core (5P30DK036836-35). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10160880. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*